Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Ildong Pharmaceutical Wins License To Sell Shionogi's IPF Drug In Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ildong Pharmaceutical Co., Ltd. said it plans to launch Shionogi & Co., Ltd.'s idiopathic pulmonary fibrosis product Pirespa (pirfenidone) in Korea in the first half of 2012 under an in-licensing deal signed July 11

You may also be interested in...



Korea's Hyundai Introduces Emergency Contraceptive ellaOne To Asia With No Additional Post-marketing Requirements

SEOUL - South Korea's Hyundai Pharm. Co. has launched HRA Pharma's oral emergency contraceptive ellaOne (ulipristal acetate) in South Korea, after Korea FDA granted the drug its first market approval in Asia

Korea's Hyundai Introduces Emergency Contraceptive ellaOne To Asia With No Additional Post-marketing Requirements

SEOUL - South Korea's Hyundai Pharm. Co. has launched HRA Pharma's oral emergency contraceptive ellaOne (ulipristal acetate) in South Korea, after Korea FDA granted the drug its first market approval in Asia

In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant

SEOUL - Korea's sixth-largest pharma JW Choongwae Pharmaceutical Corp. has signed a memorandum of understanding with Kazakhstan's JSC Chempharm to build a manufacturing plant in Kazakhstan on a turn-key basis

Related Content

Latest News
UsernamePublicRestriction

Register

SC078582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel